GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incanthera PLC (AQSE:INC) » Definitions » Tax Provision

Incanthera (AQSE:INC) Tax Provision : £0.08 Mil (TTM As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Incanthera Tax Provision?

Incanthera's tax provision for the six months ended in Sep. 2023 was £0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2023 was £0.08 Mil.


Incanthera Tax Provision Historical Data

The historical data trend for Incanthera's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incanthera Tax Provision Chart

Incanthera Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Tax Provision
0.10 0.11 0.08 0.08

Incanthera Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Tax Provision Get a 7-Day Free Trial - 0.08 - 0.08 -

Incanthera Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Incanthera (AQSE:INC) Business Description

Traded in Other Exchanges
N/A
Address
76 King Street, Manchester, GBR, M2 4NH
Incanthera PLC is a specialist dermatology and oncology company focused on transforming cancer treatment by creating environments in which cancer cannot survive. It identifies and develops solutions to current clinical, commercially relevant unmet needs, utilising a new technology. The company's current products are Sol, EP0015, Equin and Duo-C. The company has one segment, namely the development of pharmaceutical products all within the United Kingdom.

Incanthera (AQSE:INC) Headlines

No Headlines